METHOD DEVELOPMENT AND VALIDATION OF ACALABRUTINIB DRUG IN PURE FORM AND PHARMACEUTICAL DOSAGE FORMS BY RP-HPLC

Download Article
ALAM SRAVANI, P.MANICHANDRIKA, J. SARITHA RANI, SUNKU SREYA, SONAMONI SINDHUJA, SINGAM SNEHA, BORKUTE SRILATHA

A novel, simple, accurate, precise, sensitive and specific analytical RP-HPLC method wasdeveloped and validated for the quantitative estimation of Acalabrutinib in bulk drugs and pharmaceutical dosage form. Chromatographic separation was achieved on an Symmetry ODS C18 (4.6×250mm, 5µm) analytical column using mobile phase composition of methanol and Phosphate Buffer in ratio of (35: 65 v/v) that was set at a flow rate of 1.0μl/min with detection of 235 nm. The retention time of Acalabrutinib was found to be 3.006min. The drug was analyzed by following the guidelines of the International conference on Harmonization (ICH). This drug showing linearity in the concentration range of 6-14µg/ml and the correlation coefficient showing R2 = 0.9996. The % Recoveries showing within the limits. The presentation of the method was validated according to the present ICH guidelines for accuracy, precision and robustness, Linearity, limit of quantification, limit of detection linearity.

Acalabrutinib, RP-HPLC, Method Development, Accuracy, Precision.